Overview
Prosoma is a company that focuses on mental health care in oncology by providing evidence-based digital solutions. Their products are designed as Class I medical devices in compliance with HIPAA and FDA regulations in the US, and they adhere to the European MDR 2017/745 standards. They also follow ISO 13485 for medical device quality management and maintain high standards in data security and protection.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2018-10-11. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
16 public aid cases recorded, with a total value of $6,367,212.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 20, 2025 | Aid for SME participation in trade fairs | $10,045 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Nov 20, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $7,805 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Apr 22, 2025 | Aid for research and development projects: experimental development | $732,084 | Prezes Agencji Badań Medycznych |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $4,565,700.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-06-23 | Rozwój eksportu Living Well przez udział w WHX Dubaj 2026 | $17,916 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2024-03-01 | Opracowanie aplikacji do zarządzania symptomami okołochorobowymi oraz automatycznego generowania spersonalizowanej terapii psychoonkologicznej w oparciu o AI. | $1,763,874 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2023-01-01 | SNMGP (Serious Narrative Micro-Gaming Platform) – opracowanie platformy tworzenia i udostępniania narracyjnych mikrogier poważnych do mobilnych cyfrowych terapii osób w kryzysie psychicznym | $1,636,620 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The President of the Management Board is authorised to represent the company and submit declarations on its behalf independently, or a member of the management board acting jointly with the President of the Management Board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Prosoma Holdings B.v. (besloten Vennootschap Met Beperkte Aansprakelijkheid) | 2,090 | $28,227.98 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Marek Lech Ostrowski (40)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Gabos Softwaresp. z o.o. | $4,744,771.33 | gabos.pl | |
| Radpointsp. z o.o. | $4,651,079.57 | radpoint.pl | |
| Absyscosp. z o.o. | $3,831,290.98 | absysco.pl | |
| ProactaS.A. | $3,747,821.54 | proacta.pl | |
| Apzumisp. z o.o. + limited partnership | $3,507,188.76 | apzumi.com | |
| Spyrosoft ConnectS.A. | $3,219,008.34 | spyro-soft.com | |
| Revolve Healthcaresp. z o.o. | $2,789,395.36 | revolve.pro | |
| Space Itsp. z o.o. | $2,219,527.26 | spaceit.tech | |
| Medcore Projectsp. z o.o. | $2,028,836.27 | medcoreproject.pl | |
| Powermedsp. z o.o. | $768,470.48 | powermed.com.pl |
Change history
| Date | Event |
|---|---|
| 2026-04-20 | Share capital change (102,500.00 PLN → 104,500.00 PLN) |
| 2025-07-16 | Share capital change (101,500.00 PLN → 102,500.00 PLN) |
| 2025-07-16 | PKD change (Removed: 47.91.Z, 58.21.Z, 58.29.Z, 59.13.Z, 62.01.Z, 70.22.Z, 71.20.B; Added: 47.1, 47.7, 58.2, 62.10.B, 70.20.Z, 71.20.C, 73.12.Z) |
| 2023-01-11 | Share capital change (95,500.00 PLN → 101,500.00 PLN) |
| 2022-08-31 | Share capital change (9,550.00 PLN → 95,500.00 PLN) |
FAQ
Last updated: 2026-04-20